COVID-19 and Vitamin D: Length of Hospital Stay and Mortality

Completed

• Conditions: Vitamin D Deficiency; COVID-19 Pandemic

• Registration Number: NCT05221983
• Lead Sponsor: Yuksek Ihtisas University

Brief Summary

The lack of a pharmacological treatment in the COVID-19 pandemic has pushed scientists to search for this issue. Maintaining optimal health is parallel to adequate and balanced nutrition. In this context, can the protective properties of vitamin D play an important role in this pandemic? brought with it the thought. In this study, it was aimed to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease.

Detailed Description

This research was conducted to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease. For this, the approval of the Ministry of Health and then the ethics committee was obtained. For this reason, patients with positive PCR tests and hospitalized patients with vitamin D levels in their biochemistry were included in the study.

The data of the patients were obtained from the medical records. Information such as age, gender, comorbidities, length of hospital stay, vitamin D level were included in the study. According to the statistical analyzes obtained from these data, it has been shown that vitamin D level has no effect on mortality and hospital stay in COVID-19 disease.

Study Timeline

• Study Start: 2021-08-21
• Primary Completion: 2021-11-09
• Study Completion: 2021-11-16
• Status Verified: 2022-02
• Study First Submitted: 2022-02-02
• Study First Submitted QC: 2022-02-02
• Study First Posted: 2022-02-03
• Last Update Submitted: 2022-02-03
• Last Update Posted: 2022-02-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 168

Inclusion Criteria

• COVID-19 PCR (Polymerase Chain Reaction) test positive
• Vitamin D level in biochemical parameters
• Adult patients hospitalized for COVID-19

Exclusion Criteria

-Patients using drugs that may affect vitamin D absorption, such as corticosteroids, cholesterol-lowering agents, phenobarbital and phenytoin-containing agents

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Level of Vitamin D	1 month later	Vitamin D levels of patients with a diagnosis of COVID-10. These results were categorized at the level of deficiency/insufficiency/normal.
Relationship between vitamin D level and hospital stay	1 month later	Length of hospital stay by categorized vitamin D level.
Relationship between vitamin D level and mortality	1 month later	Relationship between survival and death by categorized vitamin D level.

Secondary Outcome Measures

Name	Time	Method
Effects of additional diseases (Diabetes mellitus, hypertension, etc.) on hospital stay and mortality	1 month later.	Evaluation of the impact of comorbidities on survival during COVID-19 disease.

Trial Locations

Locations (1)

Republic of Turkey Ministry of Health Ankara City Hospitals Neurology-Orthopedics Hospital; 🇹🇷 Ankara, Turkey